Exicure, Inc.
8045 Lamon Avenue
Suite 410
Skokie
Illinois
60077
United States
Tel: 847-673-1700
Fax: 847-556-6411
Website: http://www.exicuretx.com/
140 articles with Exicure, Inc.
-
Exicure, Inc. Announces Termination of AbbVie and Ipsen Collaboration Agreements
12/14/2022
Exicure, Inc. an early-stage biotechnology company historically focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets, announced the termination of its collaboration agreements with AbbVie, Inc. and Ipsen BioPharm Limited.
-
Exicure, Inc. Reports Third Quarter 2022 Financial Results and Provides Corporate Update
11/14/2022
Exicure, Inc. (Nasdaq: XCUR), an early-stage biotechnology company historically focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets, today reported financial results for the quarter ended September 30, 2022 and provided an update on its business strategy and corporate progress.
-
NeuBase announced a strategic restructuring, diverting resources from its Huntington's program and shedding 60% of its workforce.
-
Shares of Exicure, Inc. are falling after the company announced a strategic initiative that casts doubts on its future developmental programs.
-
Exicure, Inc. Enters Into Definitive Agreement With CBI USA, Inc. for $5.4 Million Equity Financing and Announces Implementation of Strategic Measure to Reduce Cash Burn and Prioritize Strategic Alternatives
9/26/2022
Exicure, Inc. (NASDAQ: XCUR) today announced plans to restructure the Company and align resources to continue exploring strategic alternatives that maximize stockholder value.
-
Exicure Announces Presentation at Chardan’s 6th Annual Genetic Medicines Conference
9/1/2022
Exicure, Inc. (NASDAQ: XCUR), an early-stage biotechnology company focused on the development of next generation nucleic acid therapies targeting RNA to address both genetic and non-genetic neurological disorders and hair loss disorders, today announced that CEO Matthias Schroff will provide a live presentation at the 2022 Chardan Genetic Medicines Conference, occurring October 3-4, 2022.
-
Exicure, Inc. Reports Second Quarter 2022 Financial Results and Corporate Progress
8/15/2022
Exicure, Inc. (Nasdaq: XCUR), an early-stage biotechnology company focused on the development of next generation nucleic acid therapies targeting RNA to address both genetic and non-genetic neurological and hair loss disorders, today reported financial results for the quarter ended June 30, 2022 and provided an update on its business strategy and corporate progress.
-
Exicure, Inc. Regains Compliance with Nasdaq Minimum Bid Price Requirement
7/20/2022
Exicure, Inc. announced that on July 19, 2022, it received a letter from the Office of General Counsel of The Nasdaq Stock Market LLC informing it that Nasdaq has confirmed that the Company has regained compliance with the $1.00 per share minimum bid price requirement pursuant to Nasdaq Listing Rule 5450 and that the Company is in compliance with all applicable listing standards.
-
Exicure, Inc. Announces Receipt of Nasdaq Notice of Non-compliance and Implementation of One-for-Thirty Reverse Stock Split
6/29/2022
Exicure, Inc. announced that, following the implementation of a one-for-thirty reverse stock split at 5:00 p.m. EDT today, the Company’s common stock will begin trading on a split-adjusted basis on Nasdaq effective with the open of business tomorrow, Thursday, June 30, 2022.
-
Exicure, Inc. Announces Adjournment of Annual Meeting of Stockholders - May 27, 2022
5/27/2022
Exicure, Inc., an early-stage biotechnology company focused on the development of next generation nucleic acid therapies targeting RNA to address both genetic and non-genetic neurological disorders and hair loss disorders, announced that the Company’s Annual Meeting of Stockholders held in virtual format on Friday, May 27, 2022 at 1:00 p.m.
-
Exicure Announces Presentation at 2022 H.C. Wainwright Global Life Sciences Conference
5/17/2022
Exicure, Inc. (NASDAQ: XCUR), an early-stage biotechnology company focused on the development of next generation nucleic acid therapies targeting RNA to address both genetic and non-genetic neurological disorders and hair loss disorders, today announced that CEO Matthias Schroff will provide a virtual presentation at the 2022 H.C. Wainwright Global Life Sciences Conference, occurring May 23-26, 2022.
-
Exicure, Inc. Reports First Quarter 2022 Financial Results and Corporate Progress
5/16/2022
Exicure, Inc. reported financial results for the quarter ended March 31, 2022 and provided an update on its business strategy and corporate progress.
-
Exicure to Present at Upcoming TIDES USA Oligonucleotide & Peptide Therapeutics Conference
5/9/2022
Exicure, Inc. today announced a poster presentation at TIDES USA 2022, May 9-12, 2022.
-
Exicure, Inc. Reports Full Year 2021 Financial Results and Corporate Progress
3/25/2022
Exicure, Inc. today reported full year financial results for the quarter and year ended December 31, 2021 and provided an update on its business strategy and corporate progress.
-
Exicure, Inc. Announces Leadership Transition and Changes to the Board of Directors
2/4/2022
Exicure, Inc. Announces Leadership Transition and Changes to the Board of Directors.
-
StrideBio, Exicure and Syndax Pharmaceuticals tapped new CEOs.
-
Exicure, Inc. Announces $11.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
12/14/2021
The gross proceeds to the Company from this offering are expected to be approximately $11.5 million, before deducting the placement agent’s fees and other offering expenses payable by the Company.
-
Exicure, Inc. Announces Results of Internal Investigation and Implementation of Strategic Measures to Reduce Cash Burn and Prioritize Pipeline Focus
12/10/2021
Exicure, Inc.® announced the results of its previously disclosed independent internal investigation and a number of strategic actions aimed to reduce cash spend and prioritize the Company’s therapeutic pipeline.
-
Exicure, Inc. Reports Third Quarter 2021 Financial Results and Corporate Progress
11/19/2021
Exicure, Inc. today reported financial results for the quarter ended September 30, 2021 and provided an update on corporate progress.
-
Exicure to Present at Upcoming Scientific Conferences - Oct 28, 2021
10/28/2021
Exicure, Inc.®, a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid technology, announced presentations at the following scientific conferences during the month of November: